Quince Therapeutics Inc

CEO Thye Dirk Exercises $3.08‑Value Stock Option Amid Surge of Insider Trades at Quince Therapeutics【News Flash】

Quince Therapeutics’ CEO’s 1‑million share option exercise signals insider confidence in the bone‑disease pipeline and may hint at a valuation reset for investors.

Quince Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

24/01/2026, 02:40

3 minutes to read

Quince Therapeutics CEO Secures $0 Option, Betting on 2029 Break‑through Amid Market Volatility

Quince Therapeutics insider buying shows CEO confidence in bone‑targeted pipeline; 200k options at $0.00 highlight potential dilution and 2029 milestone focus.

Quince Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

24/01/2026, 02:23

3 minutes to read